Pomerantz_LLP investigates Doximity securities fraud
Analysis based on 14 articles · First reported May 21, 2026 · Last updated Jun 29, 2026
The market is negatively impacted by the investigation into Doximity, as its stock price has already fallen significantly. This event could lead to a class action lawsuit, potentially resulting in substantial financial penalties for Doximity and affecting investor confidence in the healthcare technology sector.
Pomerantz LLP is investigating Doximity for alleged securities fraud and unlawful business practices. This investigation follows Doximity's announcement of its fourth quarter and fiscal year 2026 financial results on May 13, 2026, which included lower-than-expected revenue guidance and adjusted EBITDA. Doximity's management, including CEO Jeff Tangney, attributed the gross margin impact to higher AI compute costs and increased AI investment. Following this news, Doximity's stock price dropped by 23% on May 14, 2026, closing at $18.01 per share. Pomerantz LLP is now advising investors to contact them regarding potential claims.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard